The fact that CYP1A1 is almost completely depleted in primary breast tumor specimen (Fig 6), suggests that a potentially increased expression of CYP1A1 in the heterogeneous immune cell compartment under such tumor-associated inflammatory conditions does not suffice to compensate for the downregulation in the tumor cells. This evidence concerns the gene CYP1A1 and breast neoplasm.